IRIS
CICHERO, ELENA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 11.719
AS - Asia 1.489
NA - Nord America 739
SA - Sud America 123
AF - Africa 19
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 14.092
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 11.469
US - Stati Uniti d'America 707
SG - Singapore 640
CN - Cina 376
VN - Vietnam 286
FR - Francia 88
BR - Brasile 73
HK - Hong Kong 68
DE - Germania 36
FI - Finlandia 36
JP - Giappone 22
AR - Argentina 20
MX - Messico 20
IN - India 17
GB - Regno Unito 15
CH - Svizzera 12
ES - Italia 11
BD - Bangladesh 10
CA - Canada 10
IQ - Iraq 10
CL - Cile 9
ID - Indonesia 9
PH - Filippine 9
RU - Federazione Russa 7
VE - Venezuela 7
IE - Irlanda 6
NL - Olanda 6
TW - Taiwan 6
UA - Ucraina 6
CZ - Repubblica Ceca 5
ZA - Sudafrica 5
BO - Bolivia 4
MA - Marocco 4
PY - Paraguay 4
SA - Arabia Saudita 4
SE - Svezia 4
TH - Thailandia 4
TR - Turchia 4
CO - Colombia 3
JO - Giordania 3
PK - Pakistan 3
SI - Slovenia 3
AT - Austria 2
AU - Australia 2
ET - Etiopia 2
GY - Guiana 2
HR - Croazia 2
KZ - Kazakistan 2
LB - Libano 2
LI - Liechtenstein 2
NP - Nepal 2
PL - Polonia 2
UZ - Uzbekistan 2
AE - Emirati Arabi Uniti 1
AF - Afghanistan, Repubblica islamica di 1
AL - Albania 1
AZ - Azerbaigian 1
BN - Brunei Darussalam 1
CD - Congo 1
CI - Costa d'Avorio 1
DK - Danimarca 1
DZ - Algeria 1
EC - Ecuador 1
EE - Estonia 1
EG - Egitto 1
GE - Georgia 1
GT - Guatemala 1
IL - Israele 1
IS - Islanda 1
KE - Kenya 1
LA - Repubblica Popolare Democratica del Laos 1
LT - Lituania 1
LY - Libia 1
MN - Mongolia 1
MY - Malesia 1
PA - Panama 1
PS - Palestinian Territory 1
PT - Portogallo 1
SK - Slovacchia (Repubblica Slovacca) 1
SL - Sierra Leone 1
SN - Senegal 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 14.092
Salva come PNG Salva come JPEG
Città #
Genova 5.848
Genoa 3.787
Vado Ligure 949
Rapallo 720
Singapore 323
San Jose 282
Ashburn 106
Council Bluffs 94
Ho Chi Minh City 91
Lauterbourg 74
Hanoi 71
Hong Kong 62
Beijing 41
Milan 35
Frankfurt am Main 31
Helsinki 31
New York 28
Santa Clara 23
Tokyo 21
Bordighera 15
Mexico City 14
Biên Hòa 13
Los Angeles 12
Zurich 12
Da Nang 10
São Paulo 10
Haiphong 8
Hải Dương 8
Paris 8
Tianjin 8
Orem 7
Phủ Lý 7
Rome 7
Chicago 6
Amsterdam 5
Dallas 5
Dublin 5
Lappeenranta 5
Santiago 5
Thái Nguyên 5
Turin 5
Baghdad 4
Buffalo 4
Chennai 4
City of London 4
Guangzhou 4
Hyderabad 4
Teverola 4
Vancouver 4
Alessandria 3
Amman 3
Atlanta 3
Bari 3
Brescia 3
Campo Grande 3
Can Tho 3
Cardiff 3
Hangzhou 3
Jakarta 3
Ljubljana 3
Madrid 3
Manchester 3
Marseille 3
Naples 3
Nha Trang 3
Pisa 3
Porto Alegre 3
Quảng Ngãi 3
Salt Lake City 3
Savona 3
Stockholm 3
Addis Ababa 2
Bangkok 2
Basingstoke 2
Brno 2
Campinas 2
Caracas 2
Casalnuovo di Napoli 2
Catania 2
Cochabamba 2
Denver 2
Dhaka 2
Erbil 2
Georgetown 2
Guarulhos 2
Ha Kwai Chung 2
Istanbul 2
Jacksonville 2
Johannesburg 2
José Bonifácio 2
La Paz 2
Lahore 2
London 2
Long Xuyen 2
Manila 2
Maracaibo 2
Marbella 2
New Delhi 2
Ninh Bình 2
Novara 2
Totale 12.953
Salva come PNG Salva come JPEG
Nome #
Design, Synthesis, and Evaluation of Thyronamine Analogues as Novel Potent Mouse Trace Amine Associated Receptor 1 (mTAAR1) Agonists 267
New insights into selective PDE4D inhibitors: 3-(Cyclopentyloxy)-4-methoxybenzaldehyde O-(2-(2,6-dimethylmorpholino)-2-oxoethyl) oxime (GEBR-7b) structural development and promising activities to restore memory impairment 256
Synthesis and structure-activity relationship of aminoarylthiazole derivatives as correctors of the chloride transport defect in cystic fibrosis 241
Synthesis and biological evaluation of novel thiazole- VX-809 hybrid derivatives as F508del correctors by QSAR-based filtering tools 231
1,3-Dioxolane-based ligands incorporating a lactam or imide moiety: Structure-affinity/activity relationship at alpha(1)-adrenoceptor subtypes and at 5-HT(1A) receptors. 225
Molecular Chaperones in the Pathogenesis of Amyotrophic Lateral Sclerosis: The Role of HSPB1 222
Synthesis of new 5,6-dihydrobenzo[h]quinazoline 2,4-diamino substituted and antiplatelet/antiphlogistic activities evaluation 221
Ligand-based homology modelling of the human CB2 receptor SR144528 antagonist binding site: a computational approach to explore the 1,5-diaryl pyrazole scaffold 216
Identification of a high affinity binding site for abscisic acid on human Lanthionine synthetase component C-like protein 2 208
Fast course ALS presenting with vocal cord paralysis: clinical features, bioinformatic and modelling analysis of the novel SOD1 Gly147Ser mutation. 198
3,4,5-Trisubstituted-1,2,4-4H-triazoles as WT and Y188L mutant HIV-1 non-nucleoside reverse transcriptase inhibitors: docking-based CoMFA and CoMSIA analyses. 197
Synthesis, biological evaluation and molecular modeling of novel azaspiro dihydrotriazines as influenza virus inhibitors targeting the host factor dihydrofolate reductase (DHFR) 195
Rational design, chemical synthesis and biological evaluation of novel biguanides exploring species-specificity responsiveness of TAAR1 agonists 190
Benzimidazole-based derivatives as privileged scaffold developed for the treatment of the RSV infection: a computational study exploring the potency and cytotoxicity profiles 189
CoMFA and CoMSIA analyses on 1,2,3,4-tetrahydropyrrolo[3,4-b]indole and benzimidazole derivatives as selective CB2 receptor agonists. 186
Hit-to-lead optimization of mouse Trace Amine Associated Receptor 1 (mTAAR1) agonists with a diphenylmethane-scaffold: Design, Synthesis, and biological study 184
Fluorometric detection of protein-ligand engagement: The case of phosphodiesterase5 180
Exploring the QSAR of pyrazolo[3,4-b]pyridine, pyrazolo[3,4-b]pyridone and pyrazolo[3,4-b]pyrimidine derivatives as antagonists for A1 adenosine receptor. 179
Synthesis, in vitro antiplatelet activity and molecular modelling studies of 10-substituted 2-(1-piperazinyl)pyrimido[1,2-a]benzimidazol-4(10H)-ones 178
Discovery of Guanfacine as a Novel TAAR1 Agonist: A Combination Strategy through Molecular Modeling Studies and Biological Assays 175
Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus 172
Further Insights in the Binding Mode of Selective Inhibitors to Human PDE4D Enzyme Combining Docking and Molecular Dynamics 170
Synthesis, molecular modeling and SAR study of novel pyrazolo[5,1-f][1,6]naphthyridines as CB2receptor antagonists/inverse agonists 165
Synthesis, biological evaluation and molecular modeling of 1-oxa-4-thiaspiro- and 1,4-dithiaspiro[4.5]decane derivatives as potent and selective 5-HT1A receptor agonists 164
T137A variant is a pathogenetic SOD1 mutation associated with a slowly progressive ALS phenotype. 162
Novel sulfenamides and sulfonamides based on pyridazinone and pyridazine scaffolds as CB1receptor ligand antagonists 161
Docking-based CoMFA and CoMSIA analyses of tetrahydro-β-carboline derivatives as type-5 phosphodiesterase inhibitors. 158
CoMFA and CoMSIA analyses on 4-oxo-1,4-dihydroquinoline and 4-oxo-1,4-dihydro-1,5-, -1,6- and -1,8-naphthyridine derivatives as selective CB2 receptor agonists 155
Computational approaches for the design and chemical synthesis of novel F508del correctors in the treatment of cystic fibrosis 154
New arylsparteine derivatives as positive inotropic drugs 153
Discovery of novel VX-809 hybrid derivatives as F508del-CFTR correctors by molecular modeling, chemical synthesis and biological assays 152
Impaired Chaperone Activity of Human Heat Shock Protein Hsp27 Site-Specifically Modified with Argpyrimidine 147
New pyridazinone-4-carboxamides as new cannabinoid receptor type-2 inverse agonists: Synthesis, pharmacological data and molecular docking 147
In silico evaluation of human small heat shock protein HSP27: Homology modeling, mutation analyses and docking studies 142
New insights into PDE4B inhibitor selectivity: CoMFA analyses and molecular docking studies 142
Exhaustive CoMFA and CoMSIA analyses around different chemical entities: a ligand-based study exploring the affinity and selectivity profiles of 5-HT1A ligands 141
Exhaustive 3D-QSAR analyses as a computational tool to explore the potency and selectivity profiles of thieno[3,2-: D] pyrimidin-4(3 H)-one derivatives as PDE7 inhibitors 140
Novel pyrrolocycloalkylpyrazole analogues as CB1 ligands 140
Synthesis and structure-activity relationship of aminoarylthiazole derivatives as potential potentiators of the chloride transport defect in cystic fibrosis 140
Exploring the binding features of rimonabant analogues and acyclic CB1 antagonists: docking studies and QSAR analysis 137
Docking-based 3D-QSAR analyses of pyrazole derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors. 132
Charcot-Marie-Tooth Type 2B: A New Phenotype Associated with a Novel RAB7A Mutation and Inhibited EGFR Degradation 132
LEAD OPTIMIZATION OF MKT-077 ANALOGUES AS HSP70 ALLOSTERIC INHIBITORS COMBINED WITH F508DEL CFTR CORRECTORS: A MULTI DRUG APPROACH TO CONTRAST CYSTIC FIBROSIS 129
Structure-affinity/activity relationships of 1,4-dioxa-spiro[4.5]decane based ligands at α1 and 5-HT1A receptors. 126
Synthesis and biological evaluation of 1,3-dioxolane-based 5-HT1A receptor agonists for CNS disorders and neuropathic pain 126
Discovery of Novel Thiazole-Based SIRT2 Inhibitors as Anticancer Agents: Molecular Modeling, Chemical Synthesis and Biological Assays 125
Tricyclic pyrazoles. Part 8. Synthesis, biological evaluation and modelling of tricyclic pyrazole carboxamides as potential CB2 receptor ligands with antagonist/inverse agonist properties. 125
Combining repositioning and de novo synthesis of pyrazolo[3,4-d]pyrimidines to discover potent SIRT-2 inhibitors 124
Enantiomeric resolution of [(2,2-diphenyl-1,3-dioxolan-4-yl)methyl](2-phenoxyethyl)amine, a potent α1 and 5-HT1A receptor ligand: an in vitro and computational study 124
Further Insights Into the Pharmacology of the Human Trace Amine-Associated Receptors: Discovery of Novel Ligands for TAAR1 by a Virtual Screening Approach. 123
Exploring the effectiveness of novel benzimidazoles as CB2 ligands: synthesis, biological evaluation, molecular docking studies and ADMET prediction 123
Fight against H1N1 Influenza A Virus: Recent Insights towards the Development of Druggable Compounds 122
PYRAZOLO[3,4-d]PYRIMIDINE DERIVATIVES AS SIRTUIN INHIBITORS: DESIGN, SYNTHESIS AND PRELIMINARY in vitro EVALUATION 120
Novel biguanide-based derivatives scouted as TAAR1 agonists: synthesis, biological evaluation, ADME prediction and molecular docking studies 119
Journey on VX-809-Based Hybrid Derivatives towards Drug-like F508del-CFTR Correctors: From Molecular Modeling to Chemical Synthesis and Biological Assays 119
null 116
SIRT6 pharmacological inhibition delays skin cancer progression in the squamous cell carcinoma 114
Speeding up the identification of cystic fibrosis transmembrane conductance regulator-targeted drugs: An approach based on bioinformatics strategies and surface plasmon resonance 114
Structure-Activity Relationships within a Series of sigma1 and sigma2 Receptor Ligands: Identification of a sigma2 Receptor Agonist (BS148) with Selective Toxicity against Metastatic Melanoma 112
Novel Thiazole-Based SIRT2 Inhibitors Discovered via Molecular Modelling Studies and Enzymatic Assays 111
A family of nitrogen-containing heterocycles as sirtuin inhibitors: synthesis and invitro biological evaluation 111
Cyclic diacyl thioureas enhance activity of corrector Lumacaftor on F508del‐CFTR 110
Molecular Docking and QSAR Studies as Computational Tools Exploring the Rescue Ability of F508del CFTR Correctors 110
Scouting in silico different chemo-types of PDE4 inhibitors to guide the design of new anti-inflammatory/antioxidant agents 109
Synthesis, Biological Evaluation and Docking Studies of tetrahydrofuran- cyclopentanone- and cyclopentanol-based ligands acting at adrenergic alpha1- and 5-HT1A receptors. 108
Scouting new molecular targets for CFTR therapy: the HSC70/BAG-1 complex. A computational study. 108
Synthesis and biological evaluation of novel (thio)semicarbazone-based benzimidazoles as antiviral agents against human respiratory viruses 108
Virtual Screening in the Identification of Sirtuins' Activity Modulators 107
Discovery of a Novel Chemo-Type for TAAR1 Agonism via Molecular Modeling 107
Scouting new sigma receptor ligands: Synthesis, pharmacological evaluation and molecular modeling of 1,3-dioxolane-based structures and derivatives 107
Discovery of Novel Trace Amine-Associated Receptor 5 (TAAR5) Antagonists Using a Deep Convolutional Neural Network 107
A homology modelling-driven study leading to the discovery of the first mouse trace amine-associated receptor 5 (TAAR5) antagonists 106
Probing Allosteric Hsp70 Inhibitors by Molecular Modelling Studies to Expedite the Development of Novel Combined F508del CFTR Modulators 106
Virtual Screening Combined with Enzymatic Assays to Guide the Discovery of Novel SIRT2 Inhibitors 105
Homology modeling, docking studies and molecular dynamic simulations using GPU architecture to probe the type-11 Phosphodiesterase (PDE11) catalytic site: a computational approach for the rational design of selective inhibitors. 105
New insights into the binding features of f508del cftr potentiators: A molecular docking, pharmacophore mapping and qsar analysis approach 105
Probing In Silico the Benzimidazole Privileged Scaffold for the Development of Drug-like Anti-RSV Agents 102
In Silico and In Vitro Evaluation of the Mechanism of Action of Three VX809-Based Hybrid Derivatives as Correctors of the F508del CFTR Protein 101
null 99
Novel 1-amidino-4-phenylpiperazines as potent agonists at human taar1 receptor: Rational design, synthesis, biological evaluation and molecular docking studies 97
null 95
Insights into the structure and pharmacology of the human trace amine-associated receptor 1 (hTAAR1): homology modeling and docking studies. 94
Pyrazolo[3,4-d]pyrimidines as Sirtuin Inhibitors: A Preliminary Synthetic and Biological Study 92
New Insights into the LANCL2-ABA Binding Mode towards the Evaluation of New LANCL Agonists 91
Nbd2 is required for the rescue of mutant f508del cftr by a thiazole-based molecule: A class ii corrector for the multi-drug therapy of cystic fibrosis 90
Pharmacophore and pharmacokinetic filtering tools guiding for the design and synthesis of novel thiazole-containing and VX-809 hybrid derivatives as F508del correctors. 89
Computational studies of the binding mode and 3D-QSAR analyses of symmetric formimidoester disulfides: a new class of non-nucleoside HIV-1 reverse transcriptase inhibitors 87
Triazole-imidazo[1,2-b]pyrazoles Able to Counteract Melanoma Cell Survival Without Compromising the Viability of Healthy Keratinocytes 85
Recent strategic advances in CFTR drug discovery: an overview 84
New pyrazolyl thioureas active against the Staphylococcus genus 82
In silico drug repositioning on F508del-CFTR: a proof-of concept study on the AIFA library 81
Opportunities and challenges in the design of selective TAAR1 agonists: an editorial 80
RESCUING DEFECTIVE CFTR APPLYING A DRUG REPOSITIONING STRATEGY 80
Trace amine associated receptor 1 (TAAR1) modulators: a patent review (2010-present) 78
In silico exploration of LANCL2-ABA binding mode towards the identification of novel LANCL2 agonists 78
null 76
Acylthiocarbamates as non-nucleoside HIV-1 reverse transcriptase inhibitors: docking studies and ligand-based CoMFA and CoMSIA analyses 76
Targeting species-specific TAAR1 ligands: to date perspective of the rational drug design process 73
Recent Advances in the Discovery of SIRT1/2 Inhibitors via Computational Methods: A Perspective 72
Computational studies of the LANCL2 protein and abscissic acid towards the discovery of new ligands 72
Totale 13.389
Salva come PNG Salva come JPEG
Categoria #
all - tutte 44.371
article - articoli 40.550
book - libri 0
conference - conferenze 3.821
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 88.742
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021330 0 0 0 0 0 0 0 0 0 161 118 51
2021/20221.144 53 22 109 96 31 101 55 226 89 110 77 175
2022/2023882 85 45 16 83 165 124 1 76 157 11 97 22
2023/2024688 26 76 31 98 37 78 31 50 38 34 84 105
2024/20252.528 90 128 120 164 309 258 282 349 112 186 236 294
2025/20264.273 488 141 524 395 643 316 706 287 394 379 0 0
Totale 14.511